Q1 Earnings Estimate for AGIO Issued By HC Wainwright

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Agios Pharmaceuticals in a note issued to investors on Monday, February 24th. HC Wainwright analyst E. Bodnar anticipates that the biopharmaceutical company will earn ($1.53) per share for the quarter. HC Wainwright has a “Buy” rating and a $58.00 price target on the stock. The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($6.85) per share. HC Wainwright also issued estimates for Agios Pharmaceuticals’ Q2 2025 earnings at ($1.61) EPS, Q3 2025 earnings at ($1.40) EPS, FY2025 earnings at ($6.40) EPS, FY2026 earnings at ($7.35) EPS, FY2027 earnings at ($8.37) EPS, FY2028 earnings at ($7.33) EPS and FY2029 earnings at ($5.53) EPS.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%.

A number of other research firms also recently issued reports on AGIO. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. StockNews.com downgraded shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Royal Bank of Canada boosted their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, Scotiabank boosted their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a report on Monday, December 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. According to MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Stock Down 2.1 %

NASDAQ AGIO opened at $34.44 on Wednesday. The company has a market capitalization of $1.97 billion, a P/E ratio of 3.04 and a beta of 0.88. Agios Pharmaceuticals has a 12-month low of $27.14 and a 12-month high of $62.58. The firm has a 50-day moving average price of $33.92 and a two-hundred day moving average price of $42.86.

Insider Transactions at Agios Pharmaceuticals

In related news, insider Tsveta Milanova sold 2,804 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total value of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares of the company’s stock, valued at $608,395.08. This represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 4.93% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in Agios Pharmaceuticals by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock valued at $185,045,000 after purchasing an additional 85,339 shares during the last quarter. State Street Corp lifted its stake in Agios Pharmaceuticals by 10.2% in the 3rd quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after purchasing an additional 216,484 shares during the last quarter. Erste Asset Management GmbH bought a new position in Agios Pharmaceuticals in the 3rd quarter valued at approximately $97,199,000. Jefferies Financial Group Inc. bought a new position in Agios Pharmaceuticals in the 4th quarter valued at approximately $49,290,000. Finally, Geode Capital Management LLC lifted its stake in Agios Pharmaceuticals by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock valued at $60,326,000 after purchasing an additional 6,101 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.